

FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT

INT'L FILING NO. PCT/US2004/034755  
INT'L FILING DATE October 21, 2004  
APPLICANT Partridge  
GROUP  
EXAMINER 10/5/77420  
ATTORNEY DOCKET NO. PR60852U/Sw

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
WJ	1.	6,274,579	8/14/2001	Morgan et al.			
	2.	6,323,368	11/27/2001	Evans Graham			
	3.	6,337,328	1/8/2002	Fang et al.			
	4.	6,342,496	1/29/2002	Jerussi et al.			
	5.	6,391,875	5/21/2002	Morgan et al.			
	6.	6,734,213	5/11/2004	Partridge			
	7.	6,855,820	2/15/2005	Broom et al.			
	8.	2002/052340	5/2/2002	Jerussi et al.			
	9.	2002/052341	5/2/2002	Fang et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
WJ	10.	WO 01/62257	8/30/2001	PCT		

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

WJ	11.	PARTRIDGE et al., "Enantioselective Synthesis: The Optimum Process" in <i>Process Chemistry in the Pharmaceutical Industry</i> (Gadamanti R.G., Ed.) Marcel Dekker, New York, NY 1999, pp. 314-315
	12.	REIDER et al., Crystallization-Induced Asymmetric Transformation: Stereospecific Synthesis of a Potent Peripheral CCK Antagonist, <i>J. Org. Chem.</i> 52:955-957 (1987).
	13.	YAMADA et al., Asymmetric Reduction of a 1,5-Benzothiazepine Derivative with Sodium Borohydride-(S)- $\alpha$ -Amino Acids: An Efficient Synthesis of a Key Intermediate of Diltiazem, <i>J. Org. Chem.</i> 61:8586-8590 (1996).
	14.	PELLISIER, Dynamic Kinetic Resolution, <i>Tetrahedron</i> 59(42):8291-8327 (2003).
	15.	DEARDOFF et al., Enantioselective Hydrolysis of cis-3, 5-Diacetoxycyclopentene: 1R, 4S-(+)-4-Hydroxy-2-cyclopentenyl Acetate, <i>Org. Synth. Coll. IX</i> :487-493 (1998).
WJ	16.	JACQUES et al., "Crystallization-induced Asymmetric Transformations" in <i>Enantiomers, Racemates and Resolutions</i> , Krieger Publ., Malabar, FL 1991, Chpt. 6, pp. 369-377.

EXAMINER

HERBERT J. Lilling

DATE CONSIDERED

06/01/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.